SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001193125-17-315435
Filing Date
2017-10-20
Accepted
2017-10-20 16:42:02
Documents
2
Group Members
CHRISTOPH WESTPHAL, M.D., PH.D.LONGWOOD FUND II GP, LLCRICHARD ALDRICH

Document Format Files

Seq Description Document Type Size
1 SC 13D d479204dsc13d.htm SC 13D 81280
2 EX-99.A d479204dex99a.htm EX-99.A 5425
  Complete submission text file 0001193125-17-315435.txt   88678
Mailing Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE BUILDING 200, STE. 2203 CAMBRIDGE MA 02139 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Subject) CIK: 0001348911 (see all company filings)

IRS No.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: SC 13D | Act: 34 | File No.: 005-88797 | Film No.: 171147389
SIC: 2834 Pharmaceutical Preparations

Mailing Address 800 BOYLSTON STREET SUITE 1555 BOSTON MA 02199
Business Address 800 BOYLSTON STREET SUITE 1555 BOSTON MA 02199 617-351-2590
Longwood Fund II, L.P. (Filed by) CIK: 0001543245 (see all company filings)

IRS No.: 900792806 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D